BMO Capital initiated coverage of Certara (CERT) with a Market Perform rating and $9 price target BMO remains a big believer in the longer-run opportunities associated with modernizing the currently antiquated drug development process, but would like to see more evidence that these initiatives are gaining traction before getting more constructive on the stock, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara’s Earnings Call: Mixed Sentiment Amid Growth
- Certara price target lowered to $12 from $13 at Baird
- Certara price target lowered to $14 from $16 at Barclays
- Certara’s Mixed Performance: Strong Profitability Amidst Service Booking Challenges Leads to Hold Rating
- Certara, Inc. Reports Strong Q3 2025 Results